Search Results - "Cheng, Katherine A."

Synthetic Lethal Interaction of Combined BCL-XL and MEK Inhibition Promotes Tumor Regressions in KRAS Mutant Cancer Models by Corcoran, Ryan B., Cheng, Katherine A., Hata, Aaron N., Faber, Anthony C., Ebi, Hiromichi, Coffee, Erin M., Greninger, Patricia, Brown, Ronald D., Godfrey, Jason T., Cohoon, Travis J., Song, Youngchul, Lifshits, Eugene, Hung, Kenneth E., Shioda, Toshi, Dias-Santagata, Dora, Singh, Anurag, Settleman, Jeffrey, Benes, Cyril H., Mino-Kenudson, Mari, Wong, Kwok-Kin, Engelman, Jeffrey A.

“…KRAS is the most commonly mutated oncogene, yet no effective targeted therapies exist for KRAS mutant cancers. We developed a pooled shRNA-drug screen strategy…”
Get full text

Efficacy of BET Bromodomain Inhibition in Kras-Mutant Non―Small Cell Lung Cancer by SHIMAMURA, Takeshi, ZHAO CHEN, AKBAY, Esra, KIMMELMAN, Alec C, KUNG, Andrew L, BRADNER, James E, WONG, Kwok-Kin, SOUCHERAY, Margaret, CARRETERO, Julian, KIKUCHI, Eiki, TCHAICHA, Jeremy H, YANDI GAO, CHENG, Katherine A, COHOON, Travis J, JUN QI

“…Amplification of MYC is one of the most common genetic alterations in lung cancer, contributing to a myriad of phenotypes associated with growth, invasion, and…”
Get full text

Compromised CDK1 activity sensitizes BRCA-proficient cancers to PARP inhibition by Johnson, Neil, Li, Yu-Chen, Walton, Zandra E, Cheng, Katherine A, Li, Danan, Rodig, Scott J, Moreau, Lisa A, Unitt, Christine, Bronson, Roderick T, Thomas, Huw D, Newell, David R, D'Andrea, Alan D, Curtin, Nicola J, Wong, Kwok-Kin, Shapiro, Geoffrey I

“…This report identifies Cdk1's phosphorylation of BRCA1 as an important regulator of BRCA1's DNA repair function. Cdk1 inhibition renders cancer cells sensitive…”
Get full text

Combined EGFR/MET or EGFR/HSP90 Inhibition Is Effective in the Treatment of Lung Cancers Codriven by Mutant EGFR Containing T790M and MET by LU XU, KIKUCHI, Eiki, SHIMAMURA, Takeshi, WONG, Kwok-Kin, CHUNXIAO XU, EBI, Hiromichi, ERCAN, Dalia, CHENG, Katherine A, PADERA, Robert, ENGELMAN, Jeffrey A, JÄNNE, Pasi A, SHAPIRO, Geoffrey I

“…Tyrosine kinase inhibitors (TKI) that target the EGF receptor (EGFR) are effective in most non-small cell lung carcinoma (NSCLC) patients whose tumors harbor…”
Get full text

Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung Cancers by HATA, Aaron N, YEO, Alan, MINO-KENUDSON, Mari, WONG, Kwok-Kin, ENGELMAN, Jeffrey A, FABER, Anthony C, LIFSHITS, Eugene, ZHAO CHEN, CHENG, Katherine A, WALTON, Zandra, SAROSIEK, Kristopher A, LETAI, Anthony, HEIST, Rebecca S

“…Although several groups have demonstrated that concomitant use of MEK and phosphoinositide 3-kinase (PI3K) inhibitors (MEKi/PI3Ki) can induce dramatic tumor…”
Get full text

Heterogeneity of TERT promoter mutations status in squamous cell carcinomas of different anatomical sites by Cheng, Katherine A., BS, Kurtis, Boaz, MD, Babayeva, Sabina, MD, Zhuge, Jian, PhD, Tantchou, Irlna, MD, Cai, Dongming, MD, PhD, Lafaro, Rocco J., MD, Fallon, John T., MD, PhD, Zhong, Minghao, MD, PhD

“…Abstract Squamous cell carcinoma (SCC) can arise from different anatomical sites including the skin, head and neck, lung, esophagus, genital area, and so on…”
Get full text

Imaging of Smoking and Vaping Related Diffuse Lung Injury by Cheng, Katherine A., Nichols, Holly, McAdams, H. Page, Henry, Travis S., Washington, Lacey

“…Lung injury associated with smoking tobacco or other substances results in a variety of clinical presentations and imaging patterns, depending on mechanism of…”
Get full text

Abstract 875: Marked in vivo efficacy of combined BCLXL and MEK inhibition in KRAS mutant cancers revealed by a pooled shRNA-drug screen for genes that are “synthetically lethal” with MEK inhibitors by Corcoran, Ryan B., Cheng, Katherine A., Wong, Kwok-Kin, Engelman, Jeffrey A.

“…Abstract Although KRAS is the most commonly mutated oncogene in human cancer, no effective therapies exist for KRAS mutant cancers. Attempts to target KRAS…”
Get full text

Abstract 1126: Efficacy of BET bromodomain inhibition in Kras-positive non-small cell lung cancer by Shimamura, Takeshi, Chen, Zhao, Soucheray, Margaret, Carretero, Julian, Kikuchi, Eiki, Tchaicha, Jeremy H., Gao, Yandhi, Cheng, Katherine A., Cohoon, Travis J., Qi, Jun, Akbay, Esra A., Kimmelman, Alec C., Kung, Andrew L., Bradner, James E., Wong, Kwok Kin

“…Abstract Amplification of MYC is one of the most common genetic alterations in lung cancer, contributing to a myriad of phenotypes associated with growth,…”
Get full text

Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers co-driven by mutant EGFR containing T790M and MET by Xu, Lu, Kikuchi, Eiki, Xu, Chunxiao, Ebi, Hiromichi, Ercan, Dalia, Cheng, Katherine A., Padera, Robert, Engelman, Jeffrey A., Jänne, Pasi A., Shapiro, Geoffrey I., Shimamura, Takeshi, Wong, Kwok-Kin

“…Tyrosine kinase inhibitors (TKIs) that target the epidermal growth factor receptor (EGFR) are effective in most NSCLC patients whose tumors harbor activating…”
Get full text

Abstract PR09: Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS-mutant cancer models by Corcoran, Ryan B., Cheng, Katherine A., Hata, Aaron N., Faber, Anthony C., Ebi, Hiromichi, Coffee, Erin M., Greninger, Patricia, Brown, Ronald D., Godfrey, Jason T., Cohoon, Travis J., Song, Youngchul, Lifshits, Eugene, Shioda, Toshi, Dias-Santagata, Dora, Singh, Anurag, Settleman, Jeffrey, Benes, Cyril H., Mino-Kenudson, Mari, Wong, Kwok-Kin, Engelman, Jeffrey A.

“…Abstract Although KRAS is the most commonly mutated oncogene in human cancer, KRAS has proven difficult to target pharmacologically, and no effective therapies…”
Get full text